drugset / Trial / NCT00666484
Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of combination chemotherapy is more effective for Hodgkin lymphoma. PURPOSE: This phase II trial is studying the side effects of three different regimens of combination chemotherapy and to see how well they work in treating younger patients with Hodgkin lymphoma.
Timeline
- Start
- 2008-03
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Prednisolone | Other / unclassified | 40 mg/m2 | Oral |
| Subject | Prednisolone | Other / unclassified | 60 mg/m2 | Oral |
| Subject | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |
| Subject | procarbazine | Small molecule | 100 mg/m2 | Oral |